Having trouble accessing articles? Reset your cache.

NICE rebuffs Simponi for psoriatic arthritis

The U.K.'s NICE issued a preliminary appraisal recommending against Simponi golimumab from Johnson & Johnson (NYSE:JNJ)

Read the full 161 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE